aragen.com

AI-Powered Digital Pathology for Pulmonary Fibrosis Biomarker Quantification

Introduction

Artificial intelligence (AI) is revolutionizing digital pathology by enhancing disease diagnosis and monitoring, particularly for conditions like pulmonary fibrosis. Traditional pathology relies on labour-intensive, subjective manual examination of tissue samples, leading to variability in results. The integration of AI-driven machine learning (ML) models streamlines this process, improving the detection and quantification of biomarkers for faster, more precise, and reproducible outcomes.

Recent advances in deep learning, particularly convolutional neural networks (CNNs), have significantly improved medical imaging analysis. These AI systems process vast amounts of complex tissue data, identifying subtle patterns often imperceptible to human pathologists. In digital pathology, AI accelerates analysis, reduces variability, and enhances diagnostic confidence. By training on extensive datasets of labelled images, AI algorithms achieve remarkable precision in recognizing disease-associated patterns, including pulmonary fibrosis.

This article explores how AI-driven digital pathology is transforming the detection and quantification of pulmonary fibrosis markers in whole lung sections, unlocking new possibilities for clinical research and patient care.

AI-Driven Quantification of Collagen and α-SMA in Lung Fibrosis

Collagen deposition and α-SMA (alpha-smooth muscle actin) expression are critical biomarkers in assessing pulmonary fibrosis. Collagen reflects excessive extracellular matrix production, while α-SMA signifies fibroblast activation into myofibroblasts, which drive fibrosis progression. AI-powered digital pathology enables automated, high-precision quantification of these biomarkers in lung tissue samples.

At Aragen, our AI-driven approach leverages the Visiopharm digital pathology image analysis system to automate the quantification of collagen content and α-SMA expression in whole lung sections, enhancing efficiency and reproducibility.

Methodology

Algorithm Training:

- AI algorithms are trained using annotated images to detect mature collagen bundles around airways and blood vessels. These regions, categorized as "other tissue collagen," are excluded from further analysis.
- Non-airway (parenchymal) tissue is defined as a second region of interest (ROI), termed "tissue."

Quantification:

- Within the tissue ROI, the algorithm quantifies areas stained for collagen or α-SMA.
- Results are expressed as the positive area per total tissue area, providing precise and consistent biomarker measurements.

This AI-driven approach eliminates the variability associated with manual quantification, ensuring a more reliable assessment of lung fibrosis progression and treatment response.



Figure 1: Visiopharm Protocol for Masson's Trichrome Stain Quantification.



Figure 2: Visiopharm Protocol for IHC Stain of α-SMA Quantification.

Case Study

Evaluating Nintedanib and Pirfenidone in Bleomycin-Induced Lung Fibrosis

A case study investigated the effects of Nintedanib and Pirfenidone in a bleomycin-induced lung fibrosis model. The findings demonstrated that both drugs significantly reduced α-SMA overexpression and collagen deposition in mouse lungs.

Figures 3A and 3B illustrate the reduction of fibrosis markers following treatment, reinforcing the therapeutic potential of Nintedanib and Pirfenidone in managing pulmonary fibrosis.



Figure 3: Effects of nintedanib and pirfenidone on bleomycin-induced lung fibrosis on α-SMA expression level and collagen deposition [A]; Immunohistochemistry (IHC) Staining for α-SMA (upper panel) and Masson's Trichome staining for collagen deposition (lower panel) [B] under different treatments.

Conclusion

AI-powered digital pathology is transforming pulmonary fibrosis research and diagnostics. Key advantages include:

- **Automation:** Enhances accuracy, efficiency, and reproducibility in biomarker quantification.
- **Reliable Therapeutic Evaluation:** AI-driven analysis supports robust evaluation of anti-fibrotic treatments, as demonstrated in the case study.
- **Improved Diagnostics:** AI integration with digital pathology enhances diagnostic precision.
- **Accelerated Research:** Speeds up fibrosis research, enabling more effective therapeutic strategies.

At **Aragen,** we harness cutting-edge AI-driven digital pathology solutions to support researchers and clinicians in advancing pulmonary fibrosis diagnostics and treatment development. Contact us to explore how our expertise can elevate your research and therapeutic strategies.